4th Mar 2016 13:16
LONDON (Alliance News) - Onzima Ventures PLC said Friday that N4 Pharma Ltd, in which Onzima has a 49% stake, has acquired rights to commercialise a nano-particle vaccine delivery system from the University of Queensland.
Under the agreement, N4 will look to develop its Nuvac platform to provide improved vaccines for the likes of the Zika virus, Chikungunya, Crimean-Cpongo, Haemorrhagic Fever, Dengue virus, Ebola, Hantavirus, Lassa fever, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever and Rift Valley Fever.
"The nano particle technology can reduce the dose required to treat these vaccines and remove the need to use Alum as an adjuvant to make the vaccine effective. There are many sub unit vaccines in development to treat these diseases and N4 will be aiming to work with some of these antigens to improve their performance," said N4 Pharma Chief Executive Officer Nigel Theobald in a statement.
Shares in Onzima were up 34% at 1.14 pence Friday afternoon following the announcement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ONZ.L